Clinical trials: Risperidone, completed
Healthy Volunteers, Schizophrenia
Effects of Ketamine and Risperidone on Cognition
The primary objective of this study is: To determine the effects of ketamine, which blocks the ion-channel gated by the NMDA receptor, on performance of cognitive tasks and the extent to which these effects can be reversed by the…
- Trial name
- Schiz_2 (NCT01140620)
- Testing
- ketamine, risperidone, saline
- Where
- 3 sites in United Kingdom
- Volunteers
- 87 people, healthy volunteers welcome
- Sponsor
- University of Manchester
Schizophrenia
A Safety, Tolerability, and Pharmacokinetics Study of MK-8189 in Participants With Schizophrenia and in Healthy Participants (MK-8189-007)
This 4-panel study will evaluate the safety, tolerability, pharmacokinetics (PK) and corrected QT interval (QTc) effect of MK-8189 versus placebo, as monotherapy in healthy participants (Panel A) including those of Japanese…
- Trial name
- MDCS (NCT03565068)
- Testing
- MK-8189, Background AAP Therapy
- Where
- United States
- Volunteers
- 75 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Schizophrenia
A Study of Long-acting Injectable Risperidone in the Treatment of Patients With Schizophrenia or Schizoaffective Disorder
The purpose of this study is to document the long-term safety and tolerability of risperidone, formulated as a long-acting injectable, in the treatment of patients with schizophrenia or schizoaffective disorder; in addition, to…
- Trial name
- NCT00210691
- Testing
- Risperidone
- Volunteers
- 273 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia
Paliperidone Extended-Release (ER) Versus Risperidone for Neurocognitive Function in Patients With Schizophrenia
Primary objective: To examine whether the switch to paliperidone ER from risperidone improves cognitive function in stabilized patients with schizophrenia.
- Trial name
- NCT00827840
- Testing
- Paliperidone ER, Risperidone
- Where
- South Korea
- Volunteers
- 58 people
- Sponsor
- Chonnam National University Hospital
Metabolic Syndrome, Diabetes
Metabolic Profile and Anthropometric Changes in Schizophrenia
"No clinical differences will be found between the three antipsychotics under study - olanzapine, risperidone and haloperidol - on the patients' metabolic profile and weight. "
- Conditions
- Metabolic Syndrome, Diabetes, Obesity
- Trial name
- MetS (NCT00534183)
- Testing
- Olanzapine, Risperidone, Haloperidol
- Where
- India
- Volunteers
- 2,006 people
- Sponsor
- Central Institute of Psychiatry, Ranchi, India
Schizophrenia, Diabetes Mellitus
A Study of the Effects of Risperidone and Olanzapine on Blood Glucose (Sugar) in Patients With Schizophrenia or Schizoaffective Disorder
The purpose of this study is to assess and compare how risperidone and olanzapine, two antipsychotic medications, affect the regulation of glucose (sugar) in the body.
- Trial name
- NCT00236379
- Testing
- Olanzapine, Risperidone
- Volunteers
- 59 people
- Sponsor
- Janssen, LP
Schizophrenia
Observational Study of Long Acting Injectable Medications (LAIs) in Schizophrenia (OASIS)
The objectives of this study are to describe characteristics, treatment patterns, and outcomes of patients with schizophrenia newly initiated on 1 of 4 FDA-approved atypical Long Acting Injectable (LAI) antipsychotics (ABILIFY…
- Trial name
- NCT03919994
- Where
- 57 sites in United States
- Volunteers
- 338 people
- Sponsor
- Alkermes, Inc.
Chronic Schizophrenia, Schizoaffective Disorder
POC Study of Pipamperone Added to Stable Treatment With RIS or PAL in Chronic Schizophrenia
This Phase I/IIa Proof-of-Concept (PoC) trial is designed to assess the effect of adding a single and repeated low dose (15mg/d) of pipamperone (PIP) for 6 weeks to stable treatment with an effective dose of risperidone (RIS) or…
- Trial name
- NCT01450514
- Testing
- Pipamperone
- Where
- Belgium
- Volunteers
- 7 people
- Sponsor
- PharmaNeuroBoost N.V.
Schizophrenia, Schizoaffective Disorder
An Efficacy and Safety Study of Long-Term Risperidone Microspheres in Participants With Schizophrenia
The purpose of this study is to evaluate the long-term efficacy and safety of a long-acting injectable formulation of risperidone (an antipsychotic medication) and its influence on quality of life, in participants with…
- Trial name
- NCT00269919
- Testing
- Risperidone Long-Acting Injectable (RLAI)
- Where
- South Korea
- Volunteers
- 40 people
- Sponsor
- Janssen Korea, Ltd., Korea
Conduct Disorder, Oppositional Defiant Disorder
A Study of the Safety and Effectiveness of Risperidone for the Treatment of Conduct Disorder and Other Disruptive Behavior Disorders in Children Ages 5 to 12 With Mild, Moderate, or Borderline Mental Retardation
The purpose of the study is to assess the safety and effectiveness of oral risperidone (an antipsychotic medication) in the treatment of conduct disorder and other disruptive behavior disorders in children ages 5 to 12 with mild…
- Conditions
- Conduct Disorder, Oppositional Defiant Disorder, Disruptive Behavior Disorder
- Trial name
- NCT00250354
- Testing
- Risperidone oral solution
- Volunteers
- 110 people
- Sponsor
- Janssen Pharmaceutica N.V., Belgium
Healthy
Bioequivalence Study of Risperidone 1 mg Orally-disintegrating Tablets Under Fed Conditions
The purpose of this study is to determine the pharmacokinetics and bioequivalence of Risperidone formulations after administration of single doses to normal, healthy subjects under fed conditions.
- Trial name
- NCT01222923
- Testing
- Risperidone
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Ranbaxy Laboratories Limited
Schizophrenia
European Long-acting Antipsychotics in Schizophrenia Trial
Schizophrenia is a chronic psychiatric illness with periods of remission and relapse. Patients vary in the frequency and severity of relapse, time until relapse and time in remission.
- Trial name
- EULAST (NCT02146547)
- Testing
- Aripiprazole, Aripiprazole depot, Paliperidone
- Where
- 49 sites in Austria, Belgium and 14 more
- Volunteers
- 536 people
- Sponsor
- UMC Utrecht
Schizophrenia
An Inpatient Study Of The Efficacy, Safety, And Tolerability Of PF-02545920 In The Treatment Of Acute Exacerbation Of Schizophrenia
This study aims to evaluate whether PF-02545920 is safe and effective in the treatment of acute exacerbation of schizophrenia during a 4-week inpatient treatment period.
- Trial name
- NCT01175135
- Testing
- PF-02545920, Risperidone
- Where
- 46 sites in United States, Germany and 1 more
- Volunteers
- 259 people
- Sponsor
- Pfizer
Schizophrenia
Injection Site Tolerability of Multiple Dose Treatment With Long-acting Injectable Risperidone Administered Via Deltoid Muscle in Chronic Schizophrenia Patients.
The purpose of this study is to examine the discontinuation rate of schizophrenia patients receiving multiple sequential 2 mL injections of long acting injectable risperidone (an atypical antipsychotic medication) when…
- Trial name
- NCT00828958
- Testing
- Risperidone long-acting injectable
- Volunteers
- 53 people
- Sponsor
- Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Schizophrenia, Alcoholism
Risperidone and Desipramine in Alcohol Use and Schizophrenia
Note: In June 2013, the study design was changed from a randomized controlled study of risperidone + despiramine vs. risperidone vs. placebo to an open label pre-post study of risperidone (or risperidone-like drug) + desipramine.
- Conditions
- Schizophrenia, Alcoholism, Dual Diagnosis
- Trial name
- RADIAUS (NCT01411085)
- Testing
- Risperidone + Desipramine
- Where
- 4 sites in United States
- Volunteers
- 12 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Schizophrenia, Schizoaffective Disorder
Clozapine-Augmentation With Ziprasidone or Risperidone, a Randomized, Prospective Trial
We aim to compare the augmentation of clozapine with ziprasidone or risperidone in a randomized, prospective manner.
- Trial name
- NCT00224315
- Testing
- ziprasidone, risperidone
- Where
- Germany
- Volunteers
- 24 people
- Sponsor
- Central Institute of Mental Health, Mannheim
Schizophrenia Patients
Effect of Ashwagandha as Adjunct Therapy on BDNF and Cognitive Function in Schizophrenia Patients
This study aims to evaluate the effectiveness of Ashwagandha (Withania somnifera) as an adjunctive therapy in improving serum brain-derived neurotrophic factor (BDNF) levels and cognitive function in patients with schizophrenia…
- Trial name
- ASH-BDNF (NCT07541157)
- Testing
- Risperidone 4mg/day, Ashwagandha
- Where
- Indonesia
- Volunteers
- 80 people
- Sponsor
- Hasanuddin University
Schizophrenia
Study on Abnormal Dopamine Synthesis and Connectivity According to the Antipsychotic Treatment Response in Schizophrenia
The purpose of this study is to evaluate abnormal dopamine synthesis and connectivity according to the antipsychotic treatment response in schizophrenia.
- Trial name
- NCT02248987
- Testing
- patients treated with antipsychotics
- Where
- South Korea
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Seoul National University Hospital
Schizophrenia, Psychosis
Long-acting Injectable Antipsychotics for Mental Ill-Health in Pregnancy and Postpartum
The goal of this observational study is to learn about how long-acting injectable antipsychotic (LAIA) medications are affected by the changes that take place in the body during pregnancy, and how much an unborn baby is exposed…
- Conditions
- Schizophrenia, Psychosis, Mania, Pregnancy
- Trial name
- LAMP (NCT05766007)
- Where
- 6 sites in Nigeria
- Volunteers
- 168 people
- Sponsor
- University of Liverpool
Autistic Disorder in Children and Adolescents
A Study to Evaluate the Efficacy and Safety of Risperidone (R064766) in Children and Adolescents With Irritability Associated With Autistic Disorder
The purpose of this study is to evaluate the efficacy of risperidone compared with placebo in children and adolescents with irritability associated with autistic disorder.
- Trial name
- NCT01624675
- Testing
- Risperidone
- Where
- 17 sites in Japan
- Volunteers
- 39 people
- Sponsor
- Janssen Pharmaceutical K.K.